GB2597316A — Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
Assigned to GW Research Ltd · Expires 2022-01-26 · 4y expired
What this patent protects
The use of cannabidiol (CBD) for the treatment of epileptic seizures associated with rare epilepsy syndromes, the seizures treated are in patients diagnosed with a zinc finger DHHC domain-containing protein 9 (ZDHHC9) mutation. In a further embodiment the types of seizures includ…
USPTO Abstract
The use of cannabidiol (CBD) for the treatment of epileptic seizures associated with rare epilepsy syndromes, the seizures treated are in patients diagnosed with a zinc finger DHHC domain-containing protein 9 (ZDHHC9) mutation. In a further embodiment the types of seizures include atonic and tonic-clonic seizures. Preferably the CBD comprises greater than 98% (w/w) CBD and less than or equal to 2% (w/w) of other cannabinoids. Where the CBD is given concomitantly with one or more other anti-epileptic drugs (AED) including clobazam, valproic acid and levetiracetam. Preferably the dose of CBD is between 5 mg/kg/day to 50 mg/kg/day. Preferably the CBD used is in the form of a botanically derived purified CBD, but a synthetically produced CBD can alternatively be used.
Drugs covered by this patent
- Epidiolex (CANNABIDIOL) · Jazz Pharms Res
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.